Answers are grounded in this paper and cite their sources.
Central precocious puberty is a common pediatric endocrine disorder in girls. The diagnostic gold standard, the gonadotropin-releasing hormone (GnRH) stimulation test, is invasive, limiting its widespread use. Ultrasound-based bone age assessment is radiation-free, but its diagnostic value within an integrated model remains unvalidated. To develop a diagnostic model integrating ultrasound bone age advancement (ΔBA_OA) with clinical and biochemical markers for the differential diagnosis of central precocious puberty in girls. 269 girls initially diagnosed with precocious puberty were enrolled. Based on GnRH stimulation test results, they were divided into central precocious puberty ( n =66) and non-central precocious puberty ( n =203) groups. Clinical data, pelvic ultrasound parameters, hormone levels, and ultrasound bone age parameters were collected. Independent predictors were identified using logistic regression. Model performance was assessed by area under the curve (AUC), calibration curve, and decision curve analysis (DCA). ΔBA_OA (odds ratio (OR)=61.05), basal luteinizing hormone (LH) (OR=8.76), and insulin-like growth factor 1 (IGF-1) (OR=1.02) were independent predictors (all P <0.001). Standardized coefficients confirmed comparable contributions from ΔBA_OA ( β =0.675) and LH ( β =0.637). The model demonstrated good apparent discriminative ability (AUC=0.972, 95% confidence interval (CI): 0.950–0.993). Bootstrap internal validation with 200 resampling iterations yielded an optimism-corrected AUC of 0.968 (95% CI: 0.953–0.992), with a calibration slope of 0.906 and intercept of −0.015, indicating minimal overfitting and satisfactory calibration. The calibration curve showed good agreement (mean absolute error (MAE)=0.016), and DCA indicated positive net benefit. Discrimination remained high across subgroups (AUC 0.959–0.994), though subgroup estimates were exploratory and based on limited event numbers. The proposed model incorporating ultrasound bone age parameter ΔBA_OA with clinical and biochemical markers showed preliminary evidence of apparent discriminative ability. The model is intended as an auxiliary screening tool that may help reduce unnecessary GnRH stimulation testing, but this requires prospective validation. External validation in multicenter, large-sample studies is warranted before clinical implementation.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: